Terms: = Lung cancer AND CEP17
13 results:
1. Comparison of an amplicon-based large panel next generation sequencing (NGS) assay with conventional testing methods for MET and HER2 amplification in lung and breast cancers.
Tay TKY; Tan GS; Lee SH; Sam XX; Lim TH; Ng JWK; Tan DSW; Lim TKH
Pathology; 2024 Apr; 56(3):325-333. PubMed ID: 38195375
[TBL] [Abstract] [Full Text] [Related]
2. Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer.
Shitara K; Baba E; Fujitani K; Oki E; Fujii S; Yamaguchi K
Gastric Cancer; 2021 Jul; 24(4):780-789. PubMed ID: 33997928
[TBL] [Abstract] [Full Text] [Related]
3. Non-amplification genetic alterations of
Mehta A; Nathany S; Tripathi R; Sharma SK; Saifi M; Batra U
J Clin Pathol; 2021 Feb; 74(2):106-110. PubMed ID: 32527755
[TBL] [Abstract] [Full Text] [Related]
4. Advanced lung adenocarcinoma with coexistent HER2 mutation and amplification and response to afatinib: a case report.
Liu X; Cao Y; Li Y; Duan X
Ann Palliat Med; 2020 Mar; 9(2):483-487. PubMed ID: 32075402
[TBL] [Abstract] [Full Text] [Related]
5. [Fluorescence in situ hybridization combined with cytomorphology for the detection of lung cancer in bronchial brushing specimens].
Lu SS; Pan QJ; Cao J; Xu X; Zhao H; Shen DH
Zhonghua Zhong Liu Za Zhi; 2017 Aug; 39(8):595-599. PubMed ID: 28835082
[No Abstract] [Full Text] [Related]
6. The frequency and clinical impact of HER2 alterations in lung adenocarcinoma.
Kim EK; Kim KA; Lee CY; Shim HS
PLoS One; 2017; 12(2):e0171280. PubMed ID: 28146588
[TBL] [Abstract] [Full Text] [Related]
7. ALK gene copy number in lung cancer: Unspecific polyploidy versus specific amplification visible as double minutes.
Caliò A; Bria E; Pilotto S; Gilioli E; Nottegar A; Eccher A; Cima L; Santo A; Pedron S; Turri G; Knuutila S; Chilosi M; Vanzo F; Bogina G; Terzi A; Tortora G; Scarpa A; Loda M; Martignoni G; Brunelli M
Cancer Biomark; 2017; 18(2):215-220. PubMed ID: 28009326
[TBL] [Abstract] [Full Text] [Related]
8. Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape.
Olaussen KA; Postel-Vinay S
Ann Oncol; 2016 Nov; 27(11):2004-2016. PubMed ID: 27502726
[TBL] [Abstract] [Full Text] [Related]
9. cancer Signature Investigation: ERBB2 (HER2)-Activating Mutation and Amplification-Positive Breast Carcinoma Mimicking lung Primary.
Shih J; Bashir B; Gustafson KS; Andrake M; Dunbrack RL; Goldstein LJ; Boumber Y
J Natl Compr Canc Netw; 2015 Aug; 13(8):947-52. PubMed ID: 26285240
[TBL] [Abstract] [Full Text] [Related]
10. Correlation of HER-2/Neu protein expression and HER2 gene amplification with clinical morphological parameters of nonsmall cell lung cancer.
Kobyakov DS; Avdalyan AM; Bobrov IP; Bychkova EY; Lazarev AF; Lushnikova EL; Nepomnyashchikh LM
Bull Exp Biol Med; 2014 Oct; 157(6):789-93. PubMed ID: 25348568
[TBL] [Abstract] [Full Text] [Related]
11. HER2/cep17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer.
Kim JW; Kim JH; Im SA; Kim YJ; Han HS; Kim JS; Lee KH; Kim TY; Han SW; Jeon YK; Oh DY; Kim TY; Park IA
Cancer Chemother Pharmacol; 2013 Jul; 72(1):109-15. PubMed ID: 23673443
[TBL] [Abstract] [Full Text] [Related]
12. HER family receptor and ligand status in thymic carcinoma.
Weissferdt A; Lin H; Woods D; Tang X; Fujimoto J; Wistuba II; Moran CA
Lung Cancer; 2012 Sep; 77(3):515-21. PubMed ID: 22726920
[TBL] [Abstract] [Full Text] [Related]
13. Genetically abnormal circulating cells in lung cancer patients: an antigen-independent fluorescence in situ hybridization-based case-control study.
Katz RL; He W; Khanna A; Fernandez RL; Zaidi TM; Krebs M; Caraway NP; Zhang HZ; Jiang F; Spitz MR; Blowers DP; Jimenez CA; Mehran RJ; Swisher SG; Roth JA; Morris JS; Etzel CJ; El-Zein R
Clin Cancer Res; 2010 Aug; 16(15):3976-87. PubMed ID: 20651054
[TBL] [Abstract] [Full Text] [Related]
